9.3 Challenges and Recent Advances

Vascular tissue engineering faces significant hurdles in clinical translation. From scalability issues to mechanical property matching, engineers grapple with creating vessels that function like native ones. Thrombogenicity, immune rejection, and regulatory challenges further complicate the path to widespread adoption.

To overcome these obstacles, researchers employ various strategies. Advanced biomaterials, crosslinking techniques, and dynamic culturing aim to enhance vessel stability. Stem cell therapies, gene editing, and 3D bioprinting push the boundaries of what's possible in creating patient-specific, functional vascular grafts.

Challenges in Vascular Tissue Engineering

Challenges in clinical translation

Top images from around the web for Challenges in clinical translation

• 

  Frontiers | Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19 View original

  Is this image relevant?

• 

  Frontiers | Advances in Engineering Human Tissue Models View original

  Is this image relevant?

• 

  Frontiers | The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation View original

  Is this image relevant?

• 

  Frontiers | Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19 View original

  Is this image relevant?

• 

  Frontiers | Advances in Engineering Human Tissue Models View original

  Is this image relevant?

1 of 3

Top images from around the web for Challenges in clinical translation

• 

  Frontiers | Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19 View original

  Is this image relevant?

• 

  Frontiers | Advances in Engineering Human Tissue Models View original

  Is this image relevant?

• 

  Frontiers | The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation View original

  Is this image relevant?

• 

  Frontiers | Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19 View original

  Is this image relevant?

• 

  Frontiers | Advances in Engineering Human Tissue Models View original

  Is this image relevant?

1 of 3

• Scalability issues hinder large-scale production of engineered vessels and limit autologous cell availability
• Mechanical properties must match native vessels in strength and compliance
• Thrombogenicity increases risk of blood clot formation on engineered surfaces
• Immune rejection potential requires strategies to mitigate host immune response
• Regulatory hurdles involve complex approval process for tissue-engineered products (FDA, EMA)
• Cost-effectiveness concerns limit widespread adoption due to high production costs

Strategies for vessel stability

• Biomaterial selection combines natural polymers (collagen, elastin) with synthetic blends for tunable properties
• Crosslinking techniques enhance strength through chemical methods or improve stability via photocrosslinking
• Reinforcing elements like electrospun fibers provide structural support while nanoparticles enhance mechanical properties
• Dynamic culturing applies pulsatile flow mimicking physiological conditions and improves tissue maturation
• Multilayered vessel design replicates native structure (intima, media, adventitia)
• Surface modifications include endothelialization for long-term patency and antithrombogenic coatings (heparin, nitric oxide-releasing materials)

Advanced Approaches in Vascular Tissue Engineering

Stem cells and gene therapy potential

• Stem cell sources include mesenchymal stem cells for multi-lineage differentiation and induced pluripotent stem cells for patient-specific grafts
• Differentiation strategies employ growth factor cocktails (VEGF, PDGF) and mechanical cues to promote vascular phenotypes
• Gene therapy approaches involve overexpression of angiogenic factors (VEGF, FGF) and silencing inflammatory genes (TNF-α, IL-1β)
• Combination therapies integrate stem cell-seeded scaffolds with gene delivery systems (viral vectors, nanoparticles)
• In situ tissue regeneration utilizes cell-free scaffolds with gene vectors to recruit host cells and promote vascularization

3D bioprinting for vascular grafts

• Bioink development incorporates cell-laden hydrogels (alginate, gelatin) and decellularized extracellular matrix-based materials
• Multi-material printing combines different bioinks to mimic vessel layers and integrates support materials (PCL, PLA) for complex geometries
• High-resolution techniques include microextrusion for precise cell positioning and laser-assisted bioprinting for small-diameter vessels (< 6 mm)
• Patient-specific modeling uses medical imaging data (CT, MRI) to design custom grafts and computational fluid dynamics to optimize flow patterns
• In situ bioprinting develops portable devices for direct wound application (burn injuries, diabetic ulcers)
• Maturation strategies employ post-printing bioreactor culture to enhance tissue properties (ECM deposition, cell alignment)
• Vascularization of larger tissues involves printing vessel networks within engineered organs (liver, kidney) to improve nutrient delivery